- Home
- DNLI vs NAD Comparison
DNLI vs NAD Comparison
Compare DNLI & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNLI | NAD |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | DNLI | NAD |
|---|---|---|
| Price | $18.66 | $12.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $31.58 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 595.7K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,973.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.57 | $9.56 |
| 52 Week High | $24.35 | $11.64 |
Technical Indicators
Market Signals| Indicator | DNLI | NAD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.98 |
| Support Level | N/A | $11.94 |
| Resistance Level | N/A | $12.24 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 62.82 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.